Monash leads landmark prostate cancer studyThe Victorian Government today announced the state's largest investment in finding a cure for prostate cancer, funding a project which will bring together over 50 leading researchers and clinicians. Led...
The Victorian Government today announced the state's largest investment in finding a cure for prostate cancer, funding a project which will bring together over 50 leading researchers and clinicians.
Led by Associate Professor Mark Frydenberg at Monash University, the Cancer of Prostate Translational Research in Victoria (CAPTIV) project was today awarded a $2 million Victorian Cancer Agency research grant.
Experts from Monash University and other institutions, including Melbourne University, Peter MacCallum Cancer Centre, Epworth Health and Ludwig Institute, will investigate the genetic basis of prostate cancer with the aim of developing new pharmaceutical treatments. They will also look at the treatment options for men with low-risk prostate cancer.
Associate Professor Frydenberg said the scale of the CAPTIV project will mean a rapid translation of promising research to viable treatments.
"Being part of the largest collaborative prostate cancer research and trials program undertaken in Victoria to date, our clinicians and researchers will have unique access to clinical specimens. This will allow us to perform better pre-clinical studies of promising drug treatments for early and advanced prostate cancer," Associate Professor Frydenberg said.
"Another benefit is that the CAPTIV project will encourage researchers and clinicians to work together more closely, meaning better outcomes for patients in a shorter timeframe."
Professor Gail Risbridger, CAPTIV project researcher and Research Director of the Monash Comprehensive Cancer Consortium, which supported the CAPTIV project application, said strategic collaboration was vital to effectively combat disease.
“Monash University is invested in providing better outcomes for patients with prostate cancer and that requires the input of Victoria's best people, both in the laboratory and the clinic," Professor Risbridger said.
"The involvement of groups such as the Monash Comprehensive Cancer Consortium, whose member organisations, in addition to carrying out research, treat around 30 per cent of Melbourne's cancer patients, makes bringing together the right researchers and clinicians a more achievable goal. The CAPTIV project is a great example of this.”